Overview

A Phase 2, Multicenter Study of the Effect of the Addition of SNDX-275 to Continued Aromatase Inhibitor (AI) Therapy in Postmenopausal Women With ER+ Breast Cancer Whose Disease is Progressing

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The addition of SNDX-275 to an AI will result in a maximal abrogation of estrogen receptor-α mediated activity and inhibit mechanisms of resistance to the aromatase inhibitor. It is hypothesized that SNDX-275 with continued AI will increase the estimated AI clinical benefit rate (CBR) from 5% to 25% with an acceptable safety profile.

Phase:

Phase 2

Details

Lead Sponsor:

Syndax Pharmaceuticals

Treatments:

Aromatase Inhibitors
Entinostat